Podcasts about british columbia ubc

JCO PO author Dr. Dean A. Regier at the Academy of Translational Medicine, University of British Columbia (UBC), and the School of Population and Public Health, BC Cancer Research Institute shares insights into his JCO PO article, “Clinical Effectiveness and Cost-Effectiveness of Multigene Panel Sequencing in Advanced Melanoma: A Population-Level Real-World Target Trial Emulation.” Host Dr. Rafeh Naqash and Dr. Regier discuss the real-world clinical effectiveness and cost-effectiveness of multigene panels compared with single-gene BRAF testing to guide therapeutic decisions in advanced melanoma. Transcript Dr. Rafeh Naqash:Hello and welcome to JCO Precision Oncology Conversations, where we bring you engaging conversations with authors of clinically relevant and highly significant JCO PO articles. I'm your host, Dr. Rafeh Naqash, Podcast Editor for JCO Precision Oncology and Assistant Professor at the OU Health Stephenson Cancer Center in the University of Oklahoma. Today, we are excited to be joined by Dr. Dean A. Regier, Director at the Academy of Translational Medicine, Associate Professor at the School of Population and Public Health, UBC Senior Scientist at the British Columbia Cancer Research Institute, and also the senior author of the JCO Precision Oncology article entitled "Clinical Effectiveness and Cost-Effectiveness of Multigene Panel Sequencing in Advanced Melanoma: A Population-Level Real-World Target Trial Emulation." At the time of this recording, our guest's disclosures will be linked in the transcript. Dean, welcome to our podcast and thank you for joining us today. Dr. Dean Regier:Thank you. I'm delighted to be here. Dr. Rafeh Naqash:So, obviously, you are from Canada, and medicine, or approvals of drugs to some extent, and in fact approvals of gene testing to some extent is slightly different, which we'll come to learn about more today, compared to what we do in the US—and in fact, similarly, Europe versus North America to a large extent as well. Most of the time, we end up talking about gene testing in lung cancer. There is a lot of data, a lot of papers around single-gene panel testing in non-small cell lung cancer versus multigene testing. In fact, a couple of those papers have been published in JCO PO, and it has shown significant cost-effectiveness and benefit and outcomes benefit in terms of multigene testing. So this is slightly, you know, on a similar approach, but in a different tumor type. So, could you tell us first why you wanted to investigate this question? What was the background to investigating this question? And given your expertise in health economics and policy, what are some of the aspects that one tends or should tend to understand in terms of cost-effectiveness before we go into the results for this very interesting manuscript? Dr. Dean Regier:Yeah, of course, delighted to. So, one of the reasons why we're deeply interested in looking at comparative outcomes with respect to single- versus multigene testing— whether that's in a public payer system like Canada or an insurer system, a private system in the United States— is that the question around does multigene versus single-gene testing work, has not typically tested in randomized controlled trials. You don't have people randomized to multigene versus single-gene testing. And what that does, it makes the resulting evidence base, whether it's efficacy, safety, or comparative cost-effectiveness, highly uncertain. So, the consequence of that has been uneven uptake around the world of next-generation sequencing panels. And so if we believe that next-gen sequencing panels are indeed effective for our patients, we really need to generate that comparative evidence around effectiveness and cost-effectiveness. So we can go to payers, whether it be single payer or a private insurer, to say, "Here are the comparative outcomes." And when I say that uptake has been uneven, uptake there's been actually plenty, as you know, publications around that uneven uptake, whether it be in Europe, in the United States, in Canada. And so we're really interested in trying to produce that evidence to create the type of deliberations that are needed to have these types of technologies accessible to patients. And part of those deliberations, of course, is the clinical, but also in some contexts, cost-effectiveness. And so, we really start from the perspective of, can we use our healthcare system data, our learning healthcare system, to generate that evidence in a way that emulates a randomized controlled trial? We won't be able to do these randomized controlled trials for various, like really important and and reasons that make sense, quite frankly. So how can we mimic or emulate randomized controlled trials in a way that allows us to make inference around those outcomes? And for my research lab, we usually think through how do we do causal inference to address some of those biases that are inherent in observational data. So in terms of advanced melanoma, we were really interested in this question because first of all, there have been no randomized controlled trials around next-gen sequencing versus single-gene testing. And secondly, these products, these ICIs, immune checkpoint inhibitors, and BRAF and MEK inhibitors, they are quite expensive. And so the question really becomes: are they effective? And if so, to what extent are they cost-effective? Do they provide a good reason to have information around value for money? Dr. Rafeh Naqash:So now going to the biology of melanoma, so we know that BRAF is one of the tumor-agnostic therapies, it has approvals for melanoma as well as several other tumor types. And in fact, I do trials with different RAF-RAS kinase inhibitors. Now, one of the things that I do know is, and I'm sure some of the listeners know, is the DREAMseq trial, which was a melanoma study that was an NCI Cooperative Group trial that was led by Dr. Mike Atkins from Georgetown a couple of years back, that did show survival benefit of first-line immunotherapy sequencing. It was a sequencing study of whether to do first-line BRAF in BRAF-mutant melanoma followed by checkpoint inhibitors, or vice versa. And the immune checkpoint inhibitors followed by BRAF was actually the one that showed benefit, and the trial had to stop early, was stopped early because of the significant benefit seen. So in that context, before we approach the question of single-gene versus multigene testing in melanoma, one would imagine that it's already established that upfront nivolumab plus ipilimumab, for that matter, doublet checkpoint inhibitor therapy is better for BRAF-mutant melanoma. And then there's no significant other approvals for melanoma for NRAS or KIT, you know, mucosal melanomas tend to have KIT mutations, for example, or uveal melanomas, for that matter, have GNAQ, and there's no targeted therapies. So, what is the actual need of doing a broader testing versus just testing for BRAF? So just trying to understand when you started looking into this question, I'm sure you kind of thought about some of these concepts before you delved into that. Dr. Dean Regier:I think that is an excellent question, and it is a question that we asked ourselves: did we really expect any differences in outcomes between the testing strategies? And what did the real-world implementation, physician-guided, physician-led implementation look like? And so, that was kind of one of the other reasons that we really were interested is, why would we go to expanded multigene panel sequencing at all? We didn't really expect or I didn't expect an overall survival a priori. But what we saw in our healthcare system, what happened in our healthcare system was the implementation in 2016 of this multigene panel. And this panel covered advanced melanoma, and this panel cost quite a bit more than what they were doing in terms of the single-gene BRAF testing. And so when you're a healthcare system, you have to ask yourself those questions of what is the additional value associated with that? And indeed, I think in a healthcare system, we have to be really aware that we do not actually follow to the ideal extent randomized controlled trials or trial settings. And so that's the other thing that we have to keep in mind is when these, whether it's an ICI or a BRAF MEK inhibitor, when these are implemented, they do not look like randomized controlled trials. And so, we really wanted to emulate not just a randomized controlled trial, but a pragmatic randomized controlled trial to really answer those real-world questions around implementation that are so important to decision making. Dr. Rafeh Naqash:Sure. And just to understand this a little better: for us in the United States, when we talk about multigene testing, we generally refer to, these days, whole-exome sequencing with whole-transcriptome sequencing, which is like the nuclear option of of the testings, which is not necessarily cheap. So, when you talk about multigene testing in your healthcare system, what does that look like? Is it a 16-gene panel? Is it a 52-gene panel? What is the actual makeup of that platform? Dr. Dean Regier:Excellent question. Yeah, so at the time that this study is looking at, it was 2016, when we, as BC Cancer—so British Columbia is a population right now of 5.7 million people, and we have data on all those individuals. We are one healthcare system providing health care to 5.7 million people. In 2016, we had what I call our "home-brew" multigene panel, which was a 53-gene panel that was reimbursed as standard of care across advanced cancers, one of them being advanced melanoma. We have evolved since then. I believe in 2022, we are using one of the Illumina panels, the Focus panel. And so things have changed; it's an evolving landscape. But we're specifically focused on the 53-gene panel. It was called OncoPanel. And that was produced in British Columbia through the Genome Sciences Centre, and it was validated in a single-arm trial mostly around validity, etc. Dr. Rafeh Naqash:Thank you for explaining that. So now, onto the actual meat and the science of this project. So, what are some of the metrics from a health economy standpoint that you did look at? And then, methodology-wise, I understand, in the United States, we have a fragmented healthcare system. I have data only from my institution, for that matter. So we have to reach out to outside collaborators and email them to get the data. And that is different for you where you have access to all the data under one umbrella. So could you speak to that a little bit and how that's an advantage for this kind of research especially? Dr. Dean Regier:Yeah. In health economics, we look at the comparative incremental costs against the incremental effectiveness. And when we think about incremental costs, we think not just about systemic therapy or whether you see a physician, but also about hospitalizations, about all the healthcare interactions related to oncology or not that a patient might experience during their time or interactions with the healthcare system. You can imagine with oncology, there are multiple interactions over a prolonged time period depending on survival. And so what we try to do is we try to—and the benefit of the single-payer healthcare system is what we do is we link all those resource utilization patterns that each patient encounters, and we know the price of that encounter. And we compare those incremental costs of, in this case, it's the multigene panel versus the single-gene panel. So it's not just the cost of the panel, not just the cost of systemic therapy, but hospitalizations, physician encounters, etc. And then similarly, we look at, in this case, we looked at overall survival - we can also look at progression-free survival - and ask the simple question, you know, what is the incremental cost per life-year gained? And in that way, we get a metric or an understanding of value for money. And how we evaluate that within a deliberative priority setting context is we look at safety and efficacy first. So a regulatory package that you might get from, in our case, Health Canada or the FDA, so we look at that package, and we deliberate on, okay, is it safe and is it effective? How many patients are affected, etc. And then separately, what is the cost-effectiveness? And at what price, if it's not cost-effective, at what price would it be cost-effective? Okay, so for example, we have this metric called the incremental cost-effectiveness ratio, which is incremental cost in the numerator, and in this case, life-years gained in the denominator. And if it is around $50,000 or $100,000 per life-year gained—so if it's in that range, this ratio—then we might say it's cost-effective. If it's above this range, which is common in oncology, especially when we talk about ICIs, etc., then you might want to negotiate a price. And indeed, when we negotiate that price, we use the economic evaluation, that incremental cost-effectiveness ratio, as a way to understand at what price should we negotiate to in order to get value for money for the healthcare system. Dr. Rafeh Naqash:Thank you for explaining those very interesting terminologies. Now, one question I have in the context of what you just mentioned is, you know, like the drug development space, you talked about efficacy and safety, but then on the safety side, we talk about all-grade adverse events or treatment-related adverse events—two different terminologies. From a healthcare utilization perspective, how do you untangle if a patient on a BRAF therapy got admitted for a hypoxic respiratory failure due to COPD, resulting in a hospitalization from the cost, overall cost utilization, or does it not matter? Dr. Dean Regier:We try to do as much digging into those questions as possible. And so, this is real-world data, right? Real-world data is not exactly as clean as you'd get from a well-conducted clinical trial. And so what we do is we look at potential adverse event, whether it's hospitalization, and the types of therapies around that hospitalization to try- and then engage with clinicians to try to understand or tease out the different grades of the adverse event. Whether it's successful or not, I think that is a real question that we grapple with in terms of are we accurate in delineating different levels of adverse events? But we try to take the data around the event to try to understand the context in which it happens. Dr. Rafeh Naqash:Thank you for explaining that, Dean. So, again to the results of this manuscript, could you go into the methodology briefly? Believe you had 147 patients, 147 patients in one arm, 147 in the other. How did you split that cohort, and what were some of the characteristics of this cohort? Dr. Dean Regier:So, the idea, of course, is that we have selection criteria, study inclusion criteria, which included in our case 364 patients. And these were patients who had advanced melanoma within our study time period. So that was 2016 to 2018. And we had one additional year follow. So we had three total years. And what we did is that we linked our data, our healthcare system data. During this time, because the policy change was in 2016, we had patients both go on the multigene panel and on the single-gene BRAF testing. So, the idea was to emulate a pragmatic randomized controlled trial where we looked at contemporaneous patients who had multigene panel testing versus single-gene BRAF testing. And then we did a matching procedure—we call it genetic matching. And that is a type of matching that allows us to balance covariates across the patient groups, across the multigene versus BRAF testing cohorts. The idea again is, as you get in a randomized controlled trial, you have these baseline characteristics that look the same. And then the hope is that you address any source selection or confounding biases that prohibit you to have a clean answer to the question: Is it effective or cost-effective? So you address all those biases that may prohibit you to find a signal if indeed a signal is there. And so, what we did is we created—we did this genetic matching to balance covariates across the two cohorts, and we matched them one-to-one. And so what we were able to do is we were able to find, of those 364 patients in our pool, 147 in the multigene versus 147 in the single-gene BRAF testing that were very, very similar. In fact, we created what's called a directed acyclic graph or a DAG, together with clinicians to say, “Hey, what biases would you expect to have in these two cohorts that might limit our ability to find a signal of effectiveness?” And so we worked with clinicians, with health economists, with epidemiologists to really understand those different biases at play. And the genetic matching was able to match the cohorts on the covariates of interest. Dr. Rafeh Naqash:And then could you speak on some of the highlights from the results? I know you did survival analysis, cost-effectiveness, could you explain that in terms of what you found? Dr. Dean Regier:We did two analyses. The intention-to-treat analysis is meant to emulate the pragmatic randomized controlled trial. And what that does is it answers the question, for all those eligible for multigene or single-gene testing: What is the cost-effectiveness in terms of incremental life-years gained and incremental cost per life-years gained? And the second one was around a protocol analysis, which really answered the question of: For those patients who were actually treated, what was the incremental effectiveness and cost-effectiveness? Now, they're different in two very important ways. For the intention-to-treat, it's around population questions. If we gave single-gene or multigene to the entire population of advanced melanoma patients, what is the cost-effectiveness? The per-protocol is really around that clinical question of those who actually received treatment, what was the incremental cost and effectiveness? So very different questions in terms of population versus clinical cost and effectiveness. So, for the intention-to-treat, what we found is that in terms of life-years gained is around 0.22, which is around 2.5 months of additional life that is afforded to patients who went through the multigene panel testing versus the single-gene testing. That was non-statistically significant from zero at the 5% level. But on average, you would expect this additional 2.5 months of life. The incremental costs were again non-statistically significant, but they're around $20,000. And so when we look at incremental cost-effectiveness, we can also look at the uncertainty around that question, meaning what percentage of incremental cost-effectiveness estimates are likely to be cost-effective at different willingness-to-pay thresholds? Okay? So if you are willing to pay $100,000 to get one gain of life-years, around 52.8% of our estimates, in terms of when we looked at the entire uncertainty, would be cost-effective. So actually that meets the threshold of implementation in our healthcare system. So it's quite uncertain, just over 50%. But what we see is that decision-makers actually have a high tolerance for uncertainty around cost-effectiveness. And so, while it is uncertain, we would say that, well, the cost-effectiveness is finely balanced. Now, when we looked at the population, the per-protocol population, those folks who just got treatment, we actually have a different story. We have all of a sudden around 4.5 or just under 5 months of life gained that is statistically significantly different from zero, meaning that this is a strong signal of benefit in terms of life-years gained. In terms of the changes in costs or the incremental costs, they are larger again, but statistically insignificant. So the question now is, to what extent is it cost-effective? What is the probability of it being cost-effective? And at the $100,000 per life-year gained willingness-to-pay, there was a 73% chance that multigene panel testing versus single-gene testing is cost-effective. Dr. Rafeh Naqash:So one of the questions I have here, this is a clarification both for myself and maybe the listeners also. So protocol treatment is basically if you had gene testing and you have a BRAF in the multigene panel, then the patient went on a BRAF treatment. Is that correct? Dr. Dean Regier:It's still physician choice. And I think that's important to say that. So typically what we saw in both in our pre- and post-matching data is that we saw around 50% of patients, irrespective of BRAF status, get an ICI, which is appropriate, right? And so the idea here is that you get physician-guided care, but if the patient no longer performs on the ICI, then it gives them a little bit more information on what to do next. Even during that time when we thought it wasn't going to be common to do an ICI, but it was actually quite common. Dr. Rafeh Naqash:Now, did you have any patients in this study who had the multigene testing done and had an NRAS or a KIT mutation and then went on to those therapies, which were not captured obviously in the single-gene testing, which would have just tried to look at BRAF? Dr. Dean Regier:So I did look at the data this morning because I thought that might come up in terms of my own questions that I had. I couldn't find it, but what we did see is that some patients went on to clinical trials. So, meaning that this multigene panel testing allowed, as you would hope in a learning healthcare system, patients to move on to clinical trials to have a better chance at more appropriate care if a target therapy was available. Dr. Rafeh Naqash:And the other question in that context, which is not necessarily related to the gene platform, but more on the variant allele frequency, so if you had a multigene panel that captured something that was present at a high VAF, with suspicion that this could be germline, did you have any of those patients? I'm guessing if you did, probably very low number, but I'm just thinking from a cost-effective standpoint, if you identify somebody with germline, their, you know, first-degree relative gets tested, that ends up, you know, prevention, etc. rather than somebody actually developing cancer subsequently. That's a lot of financial gains to the system if you capture something early. So did you look at that or maybe you're planning to look at that? Dr. Dean Regier:We did not look at that, but that is a really important question that typically goes unanswered in economic evaluations. And so, the short answer is yes, that result, if there was a germline finding, would be returned to the patient, and then the family would be able to be eligible for screening in the appropriate context. What we have found in economic evaluations, and we've recently published this research, is that that scope of analysis is rarely incorporated into the economic evaluation. So those downstream costs and those downstream benefits are ignored. And when you- especially also when you think about things like secondary or incidental findings, right? So it could be a germline finding for cancer, but what about all those other findings that we might have if you go with an exome or if you go with a genome, which by the way, we do have in British Columbia—we do whole-genome and transcriptome sequencing through something called the Personalized OncoGenomics program. That scope of evaluation, because it's very hard to get the right types of data, because it requires a decision model over the lifetime of both the patients and potentially their family, it becomes very complicated or complex to model over patients' and families' lifetime. That doesn't mean that we should not do it, however. Dr. Rafeh Naqash:So, in summary Dean, could you summarize some of the known and unknowns of what you learned and what you're planning in subsequent steps to this project? Dr. Dean Regier:Our North Star, if you will, is to really understand the entire system effect of next-generation sequencing panels, exome sequencing, whole genomes, or whole genomes and transcriptome analysis, which we think should be the future of precision oncology. The next steps in our research is to provide a nice base around multigene panels in terms of multigene versus single-gene testing, whether that be colorectal cancer, lung cancer, melanoma, etc., and to map out the entire system implications of implementing next-generation sequencing panels. And then we want to answer the questions around, “Well, what if we do exomes for all patients? What if we do whole genomes and transcriptomes for all patients? What are the comparative outcomes for a true tumor-agnostic precision oncology approach, accounting for, as you say, things like return of results with respect to hereditary cancers?” I think the challenge that's going to be encountered is really around the persistent high costs of something like a whole-genome and transcriptome sequencing approach. Although we do see the technology prices going down—the "$1,000 genome" or “$6,000 genome" on whatever Illumina machine you might have—that bioinformatics is continuing to be expensive. And so, there are pipelines that are automated, of course, and you can create a targeted gene report really rapidly within a reasonable turnaround time. But of course, for secondary or what I call level two analysis, that bioinformatics is going to continue to be expensive. And so, we're just continually asking that question is: In our healthcare system and in other healthcare systems, if you want to take a precision oncology approach, how do you create the pipelines? And what types of technologies really lend themselves to benefits over and above next-generation sequencing or multigene panels, allowing for access to off-label therapies? What does that look like? Does that actually improve patients? I think some of the challenges, of course, is because of heterogeneity, small benefiting populations, finding a signal if a signal is indeed there is really challenging. And so, what we are thinking through is, with respect to real-world evidence methods and emulating randomized controlled trials, what types of evidence methods actually allow us to find those signals if indeed those signals are there in the context of small benefiting populations? Dr. Rafeh Naqash:Thank you so much, Dean. Sounds like a very exciting field, especially in the current day and age where cost-effectiveness, financial toxicity is an important aspect of how we improve upon what is existing in oncology. And then lots more to be explored, as you mentioned. The last minute and a half I want to ask about you as an individual, as a researcher. There's very few people who have expertise in oncology, biomarkers, and health economics. So could you tell us for the sake of our trainees and early career physicians who might be listening, what was your trajectory briefly? How did you end up doing what you're doing? And maybe some advice for people who are interested in the cost of care, the cost of oncology drugs - what would your advice be for them very briefly? Dr. Dean Regier:Sure. So I'm an economist by training, and indeed I knew very little about the healthcare system and how it works. But I was recruited at one point to BC Cancer, to British Columbia, to really try to understand some of those questions around costs, and then I learned also around cost-effectiveness. And so, I did training in Scotland to understand patient preferences and patient values around quality of care, not just quantity of life, but also their quality of life and how that care was provided to them. And then after that, I was at Oxford University at the Nuffield Department of Population Health to understand how that can be incorporated into randomized control trials in children. And so, I did a little bit of learning about RCTs. Of course, during the way I picked up some epidemiology with deep understanding of what I call econometrics, what others might call biostatistics or just statistics. And from there, it was about working with clinicians, working with epidemiologists, working with clinical trialists, working with economists to understand the different approaches or ways of thinking of how to estimate efficacy, effectiveness, safety, and cost-effectiveness. I think this is really important to think through is that we have clinical trialists, we have people with deep understanding of biostatistics, we have genome scientists, we have clinicians, and then you add economists into the mix. What I've really benefited from is that interdisciplinary experience, meaning that when I talk to some of the world's leading genome scientists, I understand where they're coming from, what their hope and vision is. And they start to understand where I'm coming from and some of the tools that I use to understand comparative effectiveness and cost-effectiveness. And then we work together to actually change our methods in order to answer those questions that we're passionate about and curious about better for the benefit of patients. So, the short answer is it's been actually quite a trajectory between Canada, the UK. I spent some time at the University of Washington looking at the Fred Hutch Cancer Research Center, looking at precision oncology. And along the way, it's been an experience about interdisciplinary research approaches to evaluating comparative outcomes. And also really thinking through not just at one point in time on-off decisions—is this effective? Is it safe? Is it cost-effective?—not those on-off decisions, but those decisions across the lifecycle of a health product. What do those look like at each point in time? Because we gain new evidence, new information at each point in time as patients have more and more experience around it. And so what really is kind of driving our research is really thinking about interdisciplinary approaches to lifecycle evaluation of promising new drugs with the goal of having these promising technologies to patients sooner in a way that is sustainable for the healthcare system. Dr. Rafeh Naqash:Awesome. Thank you so much for those insights and also giving us a sneak peek of your very successful career. Thank you for listening to JCO Precision Oncology Conversations. Don't forget to give us a rating or review, and be sure to subscribe so you never miss an episode. You can find all ASCO shows at asco.org/podcast. Thank you. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.      

Feliks Banel's guests on this special episode of CASCADE OF HISTORY – broadcast LIVE from the Museum of Vancouver in Vancouver, British Columbia – include Vivianne Gosselin, director of the museum; Coll Thrush, University of British Columbia (UBC) professor and author of the forthcoming book "Wrecked: Unsettling Histories from the Graveyard of the Pacific" from University of Washington Press; and a panel conversation with John Mackie of the Vancouver Sun; historian John Atkin; and Andy Yan, professor at Simon Fraser University (SFU). This LIVE, LOCAL AND REMOTE broadcast of CASCADE OF HISTORY was originally presented from 11am to 1pm Pacific Time on Friday, April 4, 2025 via SPACE 101.1 FM and gallantly streaming live via space101fm.org from the Museum of Vancouver in Vancouver, British Columbia, Canada. Subscribe to the CASCADE OF HISTORY podcast via most podcast platforms.

US-China relations during the Biden administration have been marked by competition and rivalry. Many of the aspects of US-China relations of the first Trump presidency were retained by the Biden administration. We have now returned to President Trump. What are we likely to see now in US foreign policy under a second Trump presidency; what will be US-China relations going forward? To explore all this I invited back into the Virtual Studio my good colleague Yves Tiberghien. Yves currently is a Professor of Political Science, Director Emeritus of the Institute of Asian Research, Konwakai Chair in Japanese Research, and Director of the Center for Japanese Research at the University of British Columbia (UBC) in Vancouver, Canada. Yves recently completed a study leave and was a visiting scholar at the Taipei School of Economics and Political Science (2023-2024). Yves specializes in comparative political economy and international political economy with an empirical focus on China, Japan, and Korea. His latest book is The East Asian Covid-19 Paradox, August 2021. Come join Yves in the Virtual Studio to examine these issues.

In this episode, we sit down with Dr. Judy Illes and Anthony Hannan to discuss the International Brain Initiative – a coalition that seeks to catalyze and advance neuroscience through international collaboration and knowledge sharing. Dr. Illes is a Professor of Neurology and a Distinguished University Scholar in Neuroethics at the University of British Columbia (UBC). She is also the Director of Neuroethics Canada at UBC, and faculty in the Brain Research Centre at UBC and at the Vancouver Coastal Health Research Institute. Her work revolves around the intersection of neurosciences and biomedical ethics, specifically looking at them from an ethical, legal, social, and political perspective. Anthony Hannon is the Head of the Neural Plasticity Laboratory at Florey Neuroscience Institutes, and an Associate Professor at the University of Melbourne, Parkville, Australia. Currently, his research focuses on cognitive and psychiatric illnesses, including conditions like Huntington's disease. Join the conversation now to find out: What the International Brain Initiative is, and how it has evolved over the years. How big data is changing science, and the importance of sharing it internationally. Obstacles that exist in the peer-review process. What the open neuroscience movement is, and how it's expanding scientific research. Want to learn more about the International Brain Initiative? Click here now! Episode also available on Apple Podcasts: http://apple.co/30PvU9C

Send us a textIn this episode with Dr Allison Ezzat we talk about the GLA:D Program (Good Life With Osteoarthritis Denmark) which is a rehabilitation program for hip and knee Osteoarthritis. We discuss: GLA:D outcomes for individuals with hip and knee osteoarthritisPros and cons of GLA:D delivered in-person vs telehealthHow to assist patients to self-management from the programHow we can market this rehabilitation program better to patientsThis episode is closely tied to Allison's Practical she did with us. With Practicals you can see exactly how top experts assess and treat specific conditions – so you can become a better clinician, faster.

It is with great pleasure that I have invited my colleague Yves Tiberghien back into the Virtual Studio for this episode on ‘Shaking the Global Order'. The US-China relationship has been marked by continuing competition and rivalry. So, I sat down again with Yves Tiberghien to examine what the current state of the US-China relationship is today while remaining mindful of the upcoming US election. I was particularly curious to see what the impact, if any, of the recent visit to Beijing by National Security Advisor Jake Sullivan might have had on current US-China relations. Yves is a Professor of Political Science, Director Emeritus of the Institute of Asian Research, Konwakai Chair in Japanese Research, and Director of the Center for Japanese Research at the University of British Columbia (UBC) in Vancouver, Canada. Yves recently completed a study leave and was a visiting scholar at the Taipei School of Economics and Political Science (2023-2024). Yves is an International Steering Committee Member at Pacific Trade and Development Conference (PAFTAD) and a visiting professor at Tokyo University and Sciences Po, Paris. He has held other visiting positions at National Chengchi University (Taiwan), GRIPS (Tokyo), and the Jakarta School of Public Policy (Indonesia). So, let's join Yves in the Virtual Studio to examine the current state of US-China relationship.

It is with great pleasure that I continued the conversation with my colleague Yves Tiberghien for this episode on ‘Shaking the Global Order'. After a short break I continued the discussion with Yves as to the current state of relations with the US and China. I was also able to extend our examination to include the impact of this competition on the Middle Power countries in the Indo-Pacific. The discussion extended to Japan, Korea, Taiwan and others. Yves is a Professor of Political Science, Director Emeritus of the Institute of Asian Research, Konwakai Chair in Japanese Research, and Director of the Center for Japanese Research at the University of British Columbia (UBC) in Vancouver, Canada. Yves recently completed a study leave and was a visiting scholar at the Taipei School of Economics and Political Science (2023-2024). Yves specializes in comparative political economy and international political economy with an empirical focus on China, Japan, and Korea. His latest book is "The East Asian Covid-19 Paradox" (August 2021) with work forthcoming on a new book titled "Game-Changer: How Covid-19 Has Reshaped Societies and Politics in East Asia". So, let's rejoin Yves in the Virtual Studio in this examination of US-China relations and its impact on the Indo-Pacific.

This episode is a continuation of the Intergenerational Engagement series of Dementia Dialogue hosted by Lisa Loiselle. Guests include Albin Soni, a student at University of British Columbia (UBC), Mario Gregorio, a passionate advocate living with dementia, and Lillian Hung, an Associate Professor in the School of Nursing at UBC.  In 2020, Dr. Hung received funding to create the Innovation in Dementia and Aging (IDEA) Lab at UBC. The purpose of the IDEA Lab is to bring together patients, family partners, researchers, health system planners, and students (as co-researchers) to create technology that will assist in the care of people with dementia and older adults, teach new skills, and prepare students for professional advancement.   During this episode, Lisa and her guests speak about the inspiration for IDEA Lab, its goals and how Mario and Albin are involved as mentor (Patient engagement partner) and mentee, respectively.  They discuss the process of ideation to creation of their technology projects through patient-oriented research, that also has the added benefit of intergenerational engagement. They also speak about their motivation to get involved in IDEA Lab. Dr. Hung also speaks about the importance of inclusion in their research and making the work important for everyone, leaving no one behind.   Beyond the research, the IDEA Lab team has built an incredible bond with each other and through their engagement, they are learning from each other, reducing stigma, and removing barriers.    Biographies:  Albin Soni (Research Assistant | UBC IDEA Lab). is currently a fourth year Biomedical Engineering student at UBC, with a focus in cellular engineering and medical devices. He is also a research assistant with the UBC Innovation in Dementia and Aging (IDEA) Lab. At IDEA Lab he pursues his interests in healthcare accessibility and innovation, while at the same time helping those with dementia and related conditions. As a long-term care home volunteer, he has become familiar with some of the hardships experienced by these individuals. The work at IDEA lab is so important to address these hardships. Outside of IDEA Lab, Albin can be found listening to music, hanging out with friends, and finding new foods to eat.   Mario Gregorio is a passionate advocate to create awareness, reduce stigma and educate the public about neurocognitive disorder or dementia. He is a member of several committees that encourage inclusiveness and accessibility for people with hidden disabilities and a recognized public speaker in universities across Canada and in the United States. He is a coauthor of several research papers about digital technology and robotics and a mentor for the University of British Columbia IDEA Lab and Simon Fraser University School of Gerontology. And is actively involved with community projects to help alleviate loneliness and foster social connections. He enjoys taking pictures during his morning walks and loves gardening.  Lillian Hung is an Associate Professor at the University of British Columbia (UBC) School of Nursing; she holds a Canada Research Chair in Senior Care. She is interested in patient-oriented research and the innovation of care for those living with dementia and their caregivers. Through the creation of the IDEA Lab, she has brought together a team of enthusiastic young students, along with patient and family partners who are pursuing innovation in dementia and aging research through co-designing of projects and sharing in the benefits of collaborative research.  Resources for website:  https://idea.nursing.ubc.ca/ 

Today my guests are Amartya Lahiri and Devashish Mitra who are joining me to discuss their latest paper for the 1991 project titled India's Development Policy Challenge. Amartya Lahiri is the Royal Bank Research Professor in the Vancouver School of Economics at the University of British Columbia (UBC). Devashish Mitra the Gerald B. and Daphna Cramer Professor of Global Affairs at the Maxwell School of Citizenship and Public Affairs, Syracuse University. We spoke about structural transformation and increasing total factor productivity, manufacturing versus services led growth, industrial policy, export led growth, how to employ India's youth in more productive sectors, and much more. Recorded July 29th, 2024. Read a full transcript enhanced with helpful links. Connect with Ideas of India Follow us on X Follow Shruti on X Follow Amartya on X Follow Devashish on X Click here for the latest Ideas of India episodes sent straight to your inbox. Timestamps (00:00:00) - Intro (00:01:27) - State of India's Structural Transformation (00:08:28) - Has India's Growth Peaked? (00:15:39) - Trade-, Export-, and Manufacturing-Led Growth (00:27:50) - Manufacturing-Led or Services-Led Growth Model? (00:47:16) - Scaling Manufacturing (00:59:38) - Labor Productivity in India (01:06:41) - Rising Protectionism (01:19:44) - Monetary Policy and Trade Policy (01:35:26) - Outro

With Guest Host: Brent Loucks Two Boeing astronauts have spent the better part of a month in space at the International Space Station after their eight-day mission was extended because of issue with their spacecraft, the Starliner. Aaron Boley, associate professor in the Department of Physics and Astronomy at the University of British Columbia (UBC) has been following the situation closely and joins Brent Loucks to explain what the situation is.

Interviewer: Lisa Meeks Interviewees: Rachel Giddings, Julia Hanes, Cheryl Holmes Description:  In this special live recording of the "Docs with Disabilities" podcast, host Lisa Meeks interviews medical professionals and educators who have worked to transform technical standards in Canadian medical education to be more inclusive of individuals with disabilities. The panel discusses the shift from restrictive technical standards to core competencies, highlighting the importance of diversity-affirming frameworks over mere accommodations. They share personal stories and insights on the impact of these changes on medical learners and the broader healthcare system. The panel delves into the motivation behind their critical evaluation of outdated technical standards and explains how the project intentionally included individuals with disabilities. This initiative, which expanded across Canada, has garnered multiple endorsements, including from the AFMC and the Medical Deans of Canada. Members of the committee meticulously re-envisioned Technical Standards for Canadian Medical Education, offering a comprehensive redefinition of the functional abilities required for medical training. This new document aims to dismantle obstacles and create a more inclusive admissions process for Canadian medical schools. Listeners will gain valuable insights into the committee's findings and recommendations, providing admissions teams with guidance on best practices and key messaging. The panel discussion explores the driving force behind this crucial initiative and examines the potential impact of the final document endorsed by the Board of the AFMC. Discover how the document offers exemplar Functional Abilities for Students Entering and Completing Medical School, paving the way for more meaningful opportunities and greater disability inclusion in Canadian medical education. Transcript Resources: https://icam-cimu.ca/  Keywords: technical standards, medical education, doctors with disabilities, ableism, healthcare, health policy, Canadian healthcare, disability inclusion Bios: Dr. Julia Hanes (she/her) is a second-year resident in the Physical Medicine and Rehabilitation at the University of British Columbia. She completed her medical degree at the University of Ottawa and her undergraduate degree in Health Sciences at McMaster University. Throughout her academic pursuits Dr. Hanes has been a keen advocate for improved inclusion and accessibility. Dr. Hanes spearheaded a program to increase accessibility in the intramural sport and recreation program, which included a longitudinal sitting volleyball intramural program. While at medical school Dr. Hanes drafted and advocated for an accessibility policy for all of the Aesculapian Society events, which included all social events, orientation events and interest group activities. This accessibility policy has now been spread to several universities across the country and discussed at institutions across the US.  Dr. Hanes is an active member of the Canadian Association of Physicians with Disabilities (CAPD). Through this group Dr. Hanes is leading a project to develop a national curriculum on disability. She has co-authored documents to help disabled student's transition from undergraduate studies to medical school, from pre-clerkship to clerkship and clerkship to residency. As a disabled student herself navigating often inaccessible educational environments, Dr. Hanes has paved a pathway for students following her to tread through. Her self-advocacy efforts prompted the creation of curb cuts, push button installation, swapping of doorknobs to handles, height adjustable tables, and more. Beyond her academic achievements, Dr. Hanes has done research in the field of childhood disability, including work to improve the quality of care and treatment of children and youth with disabilities and their families. Dr. Hanes is a passionate disability advocate and is eager to share how her experiences of ableism in medical education shapes her perspective and her advocacy efforts.   Dr. Holmes has an MD from UBC in 1984. After ten years of family practice, she enrolled in Internal Medicine at UBC, went on to complete a Critical Care fellowship at UBC and has been a Fellow of the Royal College of Physicians and Surgeons of Canada since 1999. From 2001 to July 2018, Dr. Holmes practiced critical care medicine at Kelowna General Hospital where she was involved in clinical education of medical students, residents, and fellows in the ICU. In her current role as Associate Dean Undergraduate Medical Education, she works with senior leadership at all sites of UBC to provide overall curricular oversight of all four years of the UGME program. As Head of the UBC Division of Critical Care, she is responsible for academic leadership of clinical care, education, and research in critical care. Dr. Holmes serves as Vice Chair of the UGME Deans'; Council for the Association of the Faculties of Medicine in Canada (AFMC) and collaborates on initiatives such as the Culture of Academic Medicine Initiative, the Okanagan Charter Collaborative for the AFMC and is Chairing the “Re-envisioning Technical Standards in Canadian Medical Education” Working Group. Dr. Holmes also serves on the Committee for the Accreditation of Canadian Medical Schools (CACMS) and holds the position of Chair of the CACMS Standards Subcommittee. She is on the Board of the Canadian Residency Matching Service (CaRMS) and serves as Chair of the CaRMS Board EDI Subcommittee. Through these roles, Dr. Holmes is committed to cultivating respectful, compassionate, and health-promoting environments in academic medicine, where equity, decolonization, diversity, inclusivity, accessibility, belonging (EDDIAB) and social justice are prioritized. Dr. Holmes' academic interests include promoting learner wellbeing, fostering inclusive and accessible learning environments, social accountability of medical schools, and facilitating the professional identity formation of health professionals. In 2015, she received the Canadian Association for Medical Education (CAME) Certificate of Merit for her outstanding contributions.  Rachel Giddings is a second-year medical student at the University of British Columbia (UBC), where she previously earned a Bachelor of Science in Biochemistry. Making medical education more accessible to students with disabilities is a particular interest of hers. Her current research is focused on the technical standards currently utilized by medical schools across Canada. In addition, Rachel is a member of the “Re-envisioning Technical Standards in Canadian Medical Education” Working Group. Produced by:Dr. Lisa Meeks  Audio editor: Jacob Feeman Digital Media: Katie Sullivan  

Dr. Jiaying Zhao (she/her/hers) is an Associate Professor in the Department of Psychology and the Institute for Resources, Environment and Sustainability at University of British Columbia (UBC),  Canada Research Chair in Behavioural Sustainability, and UBC Sauder Distinguished Scholar. She received her PhD in Cognitive Psychology at Princeton University. She uses psychological principles to design behavioral solutions to address financial and environmental sustainability challenges. Specifically, she designs effective behavioral interventions to alleviate poverty, promote actions to mitigate climate change, increase recycling and composting rates, and encourage biodiversity conservation actions. Sources: https://jamanetwork.com/journals/jama-health-forum/fullarticle/2814253#:~:text=The%20recognition%20of%20climate%20change,of%20US%20greenhouse%20gas%20emissions. https://www.umanitoba.ca/media/Simpson_Mason_Godwin_2017.pdf Dr. Zhao lab: https://zhaolab.psych.ubc.ca/ TED TALK: https://www.ted.com/talks/jiaying_zhao_how_to_feng_shui_your_fridge_and_other_happy_climate_hacks

The WoodCAST goes international! In this first english episode, I speak with Prof. Orlando Rojas from the University of British Columbia (UBC) about his mission to make science more impactful.  We also talk about emerging carbon capture technologies based on renewable materials. This episode was recorded on the 9th of October 2023.Support the Show.Anyone who would like to support the WoodCAST

In this episode, Nikolas Kokan, Ph.D. student at Dr. Catharine Rankin's lab, University of British Columbia (UBC), and our host Chiro talked about how humans form habits and the role of reinforcement and punishment in forming habits.Thumbnail: Emuujin BorkhuuHost: ChiroBecome a supporter of this podcast: https://www.spreaker.com/podcast/podlogy-podcast--4323328/support.

 Delve into the world of endometriosis education with Dr. Natasha Orr as she shares insights on research, advocacy, and patient-centered care. #EndometriosisAwareness #HealthcareEmpowerment Meet Natasha Orr, a researcher at the University of British Columbia (UBC) with a passion for understanding and helping people with endometriosis and chronic pelvic pain. Natasha finished her PhD in 2022, where she studied central sensitization and endometriosis associated pain. During her PhD, she spearheaded the development of endometriosis educational videos and a workshop for people with lived experience of endometriosis and their loved ones. Now, as a Postdoctoral Research Fellow, her work centers on developing online resources about endometriosis and chronic pelvic pain for healthcare providers in training using patient-oriented research and user-centered design.  Her collaborative approach involves working with patient partners throughout each step of her project, making her research not only academically significant but also accessible and engaging for the public. Natasha's commitment to reducing the delay in endometriosis care and improving healthcare providers' understanding of endometriosis and chronic pelvic pain makes her a valuable contributor to both research and advocacy in women's health. Her Postdoctoral work has received 3 grants to support project costs, a UBC Health Innovation Funding Investment award, a Michael Smith Health Research BC Convening and Collaborating Award, and a WHRI Catalyst award. She is also supported by a CIHR Postdoctoral Fellowship.Resources:Dr. Orr's Website: https://natashaorr.com/Endometriosis and Pelvic Pain Laboratory: https://endopain.endometriosis.org/_For more information on the Gynecologic Cancer Initiative, please visit https://gynecancerinitiative.ca/ or email us at info@gynecancerinitiative.ca   Where to learn more about us:  Twitter – @GCI_Cluster Instagram – @gynecancerinitiative Facebook – facebook.com/gynecancerinitiative

In this episode, Nikolas Koknat, Ph.D. student at Dr. Catharine Rankin's lab, University of British Columbia (UBC), and our host Chiro talked about how humans form habits and the role of reinforcement and punishment in forming habits.Become a supporter of this podcast: https://www.spreaker.com/podcast/podlogy-podcast--4323328/support.

Sven Butenschon is a highly accomplished hockey coach and former professional player with an impressive career spanning various hockey leagues. Born in Itzehoe, Germany, Butenschon's journey in the hockey world has left a lasting impact both as a player and as a coach.As a player, Butenschon showcased his skills as a defenseman with a left-hand shot. His talent did not go unnoticed, leading to his selection by the Pittsburgh Penguins in the third round, 57th overall, during the 1994 NHL Entry Draft. This marked the beginning of his professional career, which would later see him playing in several prominent leagues.Butenschon's playing career includes stints in the Western Hockey League (WHL), International Hockey League (IHL), National Hockey League (NHL), American Hockey League (AHL), and the Deutsche Eishockey League (DEL) in Germany. This diverse experience across different leagues attests to his versatility and adaptability as a player.Transitioning from a successful playing career to coaching, Butenschon found himself at the helm of the University of British Columbia (UBC) hockey team. His coaching prowess reached new heights as he led the team to a remarkable achievement – winning the championships for the first time in over 50 years. This historic victory not only highlighted Butenschon's leadership abilities but also brought a sense of pride and accomplishment to the UBC hockey program.Being named the U Sports Coach of the Year is a testament to Butenschon's dedication, strategic acumen, and the positive impact he has had on his players. His coaching philosophy, honed through years of experience in different hockey environments, played a crucial role in shaping a championship-winning team.

RECOVERING POLITICIANS PANEL:  TRUDEAU MEETS WITH CABINET & OTTAWA PUTS CAP ON INTERNATIONAL STUDENTS Libby Znaimer is joined by Lisa Raitt, former deputy leader of the Conservative Party of Canada, George Smitherman, former Ontario Liberal MPP for Toronto Centre who also served as a health minister, and deputy Premier and Cheri Di Novo, Former Ontario NDP MPP. Our panel discusses Prime Minister Justin Trudeau's cabinet retreat in Montreal this week, Toronto Mayor Olivia Chow's town hall meetings on the 2024 budget and Ottawa's cap on international students. WHAT THE LATEST ALZHEIMER'S REPORT TELLS US ABOUT THE DISEASE Libby Znaimer is joined by Dr. Joshua Armstrong, the lead author of The Landmark Study: The Many Faces of Dementia and can speak to the findings and the research, and Dr. Roger Wong, Alzheimer Society of Canada Board Member, Clinical Professor in the Division of Geriatric Medicine, Vice Dean (Education) in the University of British Columbia (UBC). A new report from the Alzheimer's Association of Canada, "The Many Faces of Dementia in Canada", is now out. It paints a detailed picture of how this disease is impacting Canadians across demographics and it shows that by the year 2050 the number of those living in this country with Dementia will jump by nearly 200 per cent! Our guests weigh in on the latest. WHY ARE WE HEARING ALL ABOUT THE HEALTH COMPLICATIONS PLAGUING THE ROYAL FAMILY? Libby Znaimer is now joined by Alison Eastwood, Editor-in-Chief of HELLO! Canada. In just the span of a couple weeks we've been learning about a series of health complications plaguing the Royal Family. First, we found out that Kate Middleton went in for abdominal surgery and then we also learned that King Charles is dealing with an enlarged prostate. His wife, Camilla, reportedly has been telling him to slow down during this time. And, sadly, we've also learned that Princess Sarah Ferguson, the Duchess of York, has been diagnosed with skin cancer. Why are we hearing all about these health issues and does this make the royal family feel more relatable?

Our guest, Dr Hezy Anholt, is a true world citizen. She has lived and worked in about 10 different countries. Originally from Canada, Hezy has found a second home in Malawi where she initially worked as a research veterinarian for the Lilongwe Wildlife Trust for two years. In addition to running her own wildlife vet business, she has been a PhD candidate since 2021. Through the University of British Columbia (UBC) in Canada, she studies trypanosomiasis, or ‘sleeping sickness', with a One Health approach. Malawi has the highest prevalence of this almost always fatal disease. Join our host Dr Cat Vendl on a trip into the heart of wildlife research in Malawi with Hezy. Links Hezy's PhD work with UBC: https://www.grad.ubc.ca/campus-community/meet-our-students/anholt-heather-hezy Hezy's blog post in the Lonely Conservationists on neo-colonialism: https://lonelyconservationists.com/2023/06/27/hezy-exploited-in-the-haze-of-a-dazzling-opportunity/

It is with great pleasure that I have invited my colleague Yves Tiberghien back into the Virtual Studio for this episode on ‘Shaking the Global Order'. ‘The US-China relationship has been marked by growing competition and rivalry. This increasing tension seemed to reach a dramatic moment when a high-altitude balloon originating from China flew across North American airspace from January 28 to February 4, 2023 only to be shot down over U.S. territorial waters off the coast of South Carolina. As a result China suspended all military to military communications. Meanwhile, Secretary of State Antony Blinken postponed a visit. US-China relations languished until the recent Xi-Biden summit on November 15th that took place near San Francisco at the margin of the APEC Summit. So, what is the current state of the US-China relationship today and how are the two reshaping the global order in the face of US-China relations? Yves currently is a Professor of Political Science, Director Emeritus of the Institute of Asian Research, Konwakai Chair in Japanese Research, and Director of the Center for Japanese Research at the University of British Columbia (UBC) in Vancouver, Canada. Yves is currently on study leave from UBC and is a visiting scholar at the Taipei School of Economics and Political Science (2023-2024). Yves specializes in comparative political economy and international political economy with an empirical focus on China, Japan, and Korea. His latest book is The East Asian Covid-19 Paradox. August 2021 with work forthcoming on a new book (titled 'Game-Changer: How Covid-19 Has Reshaped Societies and Politics in East Asia'). So, let's join Yves in the Virtual Studio to examine the US-China relationship

In this episode I'm delighted to welcome back Prof Mark Williams and Prof Nicola Hodges to speak about skill acquisition in sport. Mark Williams is a Senior Research Scientist at The Institute of Human and Machine Cognition (IHMC)- a not-for-profit research institute of the Florida University System and is affiliated with several Florida universities. Mark was previously at the University of Utah, where he was professor and chairman of the Department of Health, Kinesiology, and Recreation. Mark has held various senior leadership positions Liverpool John Moores University, University of Sydney and Brunel University, London. Mark's research interests focus on the neural and psychological mechanisms underpinning the acquisition and development of expertise. He has published almost 300 journal articles in peer-reviewed outlets in numerous fields including exercise and sports science Nikki is a Professor at the University of British Columbia (UBC), Vancouver in the School of Kinesiology. It is at UBC that Nikki runs the Motor Skills Laboratory where she studies the mechanisms of motor skill learning. Her research focuses on processes involved in watching, learning and predicting from others and how practice should be best structured to bring about long-term enhancement of motor skills and high-level performance (particularly in sport). She has been involved in sport-consulting and she has published over 100 peer-reviewed articles and chapters.

I have a quiet aversion to conversations about wellbeing. The term conjures images of privilege and appropriation, like the time I was instructed to wave a stick of incense at a merchandised “altar" before disrobing for a spa treatment. Over the years, I've heard many conversations in yoga studio lobbies devolve into insensitive recommendations for the latest bestseller on grief or a self-paced online course designed to transform. The word draws my attention to the thin line between holistic health and aspirations of self-optimization, control, and certainty.Quality is fine by me — I delight in an organic smoothie and consider myself a connoisseur of pillows. I buy the beeswax candles from the endcap display at the grocery store regularly. I've brokered in wellness my entire professional life, and I do believe in wellbeing. I want wellbeing for you and me and every living thing. What gets me is how ideas of wellness have become conflated with a cultural mythology around wealth. We are inundated by a profit industry built on the  premise that we are not ok and that buying something — anything — will change that. Our sense of wellbeing has become conflated with purchasing power. It's a cheap ordeal, and we know it: the epitome of what the Buddha pointed to as “false refuge.” Wellbeing can't be bottled and bought. We've tried that. We're mistrustful of being sold on miracle drugs, fad diets, and unverified health claims. We're tired of measuring ourselves by industry standards (a colossal industry, by the way — the global wellness industry was valued at over $4.5 trillion in pre-Pandemic 2019, according to the Global Wellness Institute). Discourse on wellbeing can sound tone deaf when juxtaposed with the existential challenges of our time. In the context of a growing disparity in health outcomes across income groups, for example, our cultural obsession with weight loss flaunts itself next to families unable to afford proper fruits and vegetables. We are a society of dissonance when it comes to wellbeing – constantly trying to perfect ourselves while failing to meet the basic requirements for wellbeing as outlined by Maslow's objective hierarchy of physiological needs, safety, love and belonging, esteem, and self-actualization. But what exactly is wellbeing, we might ask. A standard definition refers to our holistic health as constituted by the vital interplay of our physical, emotional, social, environmental, and spiritual layers. Less a state than an integrative process, wellbeing is our access to a wholesome, creative, dynamic, and resilient sense of equilibrium. The word for wellbeing in Sanskrit is “sukha,” which shares an etymological root with our modern English words sucrose and sugar. So there's a flavor of sweetness to wellbeing. Its original context in the Vedas, according to Monier-Williams (1964), referred to how well a chariot axle was positioned to maintain the rotational balance between wheels and support the chariot's weight, thus allowing it to move smoothly forward: "su ['good'] + kha ['aperture'] to mean originally 'having a good axle-hole.'”   Things haven't changed much in that regard – today as always, a vehicle that has good suspension is what we want when traversing the rough roads we must travel.We are talking here about receptivity and steadiness, and also about order and flow. Among the early scriptures, “sukha” is associated with “shreya,” meaning “that which produces lasting benefit” — in other words, it's enduring. Shreya is contrasted with “preya,” a word epitomizing immediate gratification. Modern researchers similarly differentiate hedonism, characterized by the instinct toward pleasure and away from pain, and eudaimonism, a more lasting sense of fulfillment through growth and purpose.Wellbeing is measured by four convergent methods: the presence of (1) positive emotions and the absence of negative emotions, (2) mature character traits, including self-directedness, cooperativeness, and self-transcendence, (3) life satisfaction or quality of life, and (4) character strengths and virtues, such as hope, compassion, and courage (Peterson and Seligman, 2004). These features interact cooperatively such that a person cannot feel good (as measured by positive emotions and life satisfaction) without doing good (as measured by maturity of character and virtuous conduct) (Cloninger, 2004).Here's a simple case study for your consideration. Social psychologist Elizabeth Dunn of the University of British Columbia (UBC) wanted to find out what kind of spending makes people happy, so she and colleagues surveyed 109 UBC students. Not surprisingly, most said they would be happier with $20 in their pocket than they would with $5. They also said they'd rather spend the money on themselves than on someone else. But when Dunn's team gave 46 other students envelopes containing either a $5 bill or a $20 bill and told them how to spend it, those who donated to charity or bought a gift reported feeling happier at the end of the day than those who spent on themselves. Herein lies the distinction between self-indulgence and self-care. A benign expression of self-indulgence might be a well-earned treat like an ice cream cone with sprinkles or a Saturday afternoon lounging on the sofa. Self-indulgence is not necessarily unhealthy, though nor is it enduring. It is simply sensory delight, known as “pāmojja” in Pali. And it can, in fact, be bought.Self-care, on the other hand, consists of the specific choices and behaviors that lead to a quality of feeling over time. Self-care is how we contribute to our own wellbeing at any given moment and under any given circumstance. It's any benevolent mechanism by which we nurture presence and alignment with our values. It's reflected in our intentions, actions, and habits, as well as in pausing to integrate and recalibrate. Self-care is setting boundaries to mitigate depletion when appropriate and equally expanding beyond the habit of navel-gazing to show up for others.Many of us sense an undercurrent of disassociation beneath the surface of our lives. We feel more emotionally isolated than ever before (a phenomenon amply attested to by recent studies, including one ranging from 1990 to 2021 which indicated a 25% decrease in the number of Americans who reported having five or more close friends). We long for more intimacy, connection, and belonging, but we've chosen social structures that reinforce individualism over community. Henry Ward Beecher posited that “the art of being happy lies in the power of extracting happiness from common things.” The practice of such extraction requires intention, engagement, awareness, and surrender to balance and nurture the dynamic facets of our humanness. Wellbeing requires both personal agency (which, yes, is a privilege) and interwoven structures of support and belonging. We might feel relaxed after a massage, but true wellbeing emerges only through the sustained practice of leaning into the kinship we share — the double entendre of our “common” things.Perhaps the most misguided notion about wellbeing is that it's a solitary pursuit, wherein the responsibility falls on individuals to succeed or fail rather than on our communal web. Fariha Róisín's book, “Who Is Wellness For? An Examination of Wellness Culture and Who It Leaves Behind,” tracks the author's personal experience of seeking healing from trauma while simultaneously exposing the wellness industrial complex and its myriad failures. “Capitalism tricks us into believing that we don't need each other,” the author poignantly shares. Somehow, glimmers are possible under extraordinary circumstances. Our teachers here are those who touch ecstatic aliveness in cycles of profound grief, who praise the rising sun in war zones. I recently heard meditation teacher Tara Brach respond when a student asked about how to stay connected to life while facing the staggering uncertainty of a child's diagnosis: “the doorway to wellbeing is always through the heart,” she softly said.  If each day falls inside each night,There exists a wellwhere clarityis imprisoned.We need to sit on the rimof the well of darknessand fish for fallen light,with patience.- Pablo Neruda, “Si cada día cae/If each day falls" Wellbeing is both a practice and the reservoir of having opened to the fullness of our felt experience — having sat “on the rim of the well of darkness and fish[ed] for fallen light” — many times over. Jarvis Jay Masters, a Buddhist writer and teacher who endured a mind-boggling 21 years of solitary confinement based on wrongful conspiracy charges, offers this sage reflection in his memoir:Over the years, I have been asked when it was that I “saw the light,” had a dream, or heard a voice. What experience created a reverberation that transformed me from the person I was then to the person I am today? The truth of the matter is that I have never changed. Rather, I have simply discovered who I've always been: the young child who knew that his life mattered, that he could make a difference in the world, and that he was born to fly. — Jarvis Jay Masters, That Bird Has My WingsJarvis re-discovered the life that matters within him.To me, the 13th c. Sufi mystic Rumi's timeless question “do you make regular visits to yourself?” offers us a compass. What could come from giving ourselves permission to meet our experience with consistency, honesty, and generosity?As it happens, I do make regular visits to myself. I'm fortunate to live on the rim of a trail system in the vast landscape of Northern New Mexico. My wonder hour, which I hold in grateful contrast to the happy hours of my younger years, is the early morning, a time that favors contemplation and communion. It's known as “Brahmamuhurta" in India — the hour of God — and referenced by David in Psalm 5: “O Lord, in the morning you hear my voice.”Cold air in my lungs, solid ground beneath my feet, I make my way along the trails around my home, slowly unspooling my heart to the juniper, the chamisa, and the pine. They receive with fraternity all that which I have to give. Most mornings, by the time the sun has pushed up the day, I can sense, along with care for the heartbroken bits, an embodied enough-ness. It's a remembered hum in my human heart. To me, this is what wellbeing must be. And it's priceless. Get full access to The Guest House at shawnparell.substack.com/subscribe

Амралтын өдрийн мэнд хүргэе. Та бүхэнтэй Podlogy багийн шинэ гишүүн Алтан-Очир (Chiro)-ын хамт IQ, танин мэдэхүйн чадварууд, оюун дүгнэлтийн алдаануудын талаар ярилцсан шинэ дугаараараа мэндчилж байна. Chiro University of British Columbia (UBC)-д сэтгэл судлалаар суралцдаг ба түүний мөрөөдөл нь хүн бүрт сэтгэл судлалын мэдлэг, мэдээллийг үнэ төлбөргүй хүргэх юм. Podlogy-д тавтай морил Chiro!

In today's episode I speak with trauma surgeons Drs. Morad Hameed and Elliott Haut. With the announcement of President Biden's first-ever federal Office of Gun Violence Prevention, today's conversation is on point. We chat gun violence in the USA and Canada and discuss the Stop The Bleed campaign. Morad and Elliott speak on what they do to prevent burnout in themselves given that they are exposed to so much trauma themselves. The STOP THE BLEED® campaign was initiated by a federal interagency workgroup convened by the National Security Council Staff, The White House. The purpose of the campaign is to build national resilience by better preparing the public to save lives by raising awareness of basic actions to stop life threatening bleeding following everyday emergencies and man-made and natural disasters.  Morad Hameed is a trauma surgeon and intensivist at the Vancouver General Hospital (VGH) and an Associate Professor of Surgery at the University of British Columbia (UBC). He completed medical school and surgical residency at the University of Alberta, graduate studies in public health at Harvard University, and fellowships in Trauma Surgery and Surgical Critical Care at the University of Miami.  Elliott Haut MD PhD is the Vice Chair of Quality, Safety, & Service, Department of Surgery, Professor of Surgery at Johns Hopkins Medicine and Editor in Chief at Trauma Surgery & Acute Care Open.

This week on the show, national politics reporter Scott Martin sits down with Sean Smukler. Sean Smukler is an associate professor in applied biology and soil science at University of British Columbia (UBC) and director of the Centre for Sustainable Food Systems at UBC Farm.  Martin and Smukler discuss the current challenges farmers are facing in Canada due to climate change – and wonder aloud where Canada is headed.  “We are facing a climate emergency, and we're pretending like it's something for the next generation to deal with. No one grasps the fact that if we don't deal with it now, the next generation can't deal with it.” - Sean Smukler To learn more about the state of Canadian agriculture in the face of climate change, read Scott Martin's full piece here.  If you like the show please consider subscribing on Apple Podcasts, Spotify, or wherever you find your podcasts. And please, rate, review, share rabble radio with your friends — it takes two seconds to support independent media like rabble. Follow us on social media across channels @rabbleca. 

In this episode, Sujani sits down with Dr. Firdosi Mehta, an adjunct professor at York University. They discuss his previous work at the WHO, the eradication of smallpox and polio, and his current work with mentoring and educating students and young professionals along their public health journeys. You'll LearnWhat motivated Dr. Mehta to pursue public health after his time in medical schoolDr. Mehta's memories of the WHO's work in eradicating smallpox and his own work towards eradicating polioHow kindness, compassion, and empathy is at the root of public healthNetworking and reputation building tips for job seekingDr. Mehta's mentoring experience and advice for students and young professionalsToday's GuestDr Mehta has over 30 years of Public Health experience, more than half of which were with the WHO. He has worked in several countries and regions of the world. Dr Mehta completed his medical education in India after which he served in the Indian Navy Defense Services. He then served in the Ministry of Health, Sultanate of Oman in various capacities for 10 years, the last being Director of Surveillance and Disease Control. Dr Mehta then joined the World Health Organization and worked in Somalia from 1998 – 2002, where he was responsible for supporting the control of TB and all other communicable diseases in a complex emergency situation. He moved from Somalia to Indonesia in 2002 in the capacity of Country Advisor Tuberculosis Control program (Mega High burden country) for seven years. Dr Mehta subsequently moved to Sri Lanka in 2009 as the WHO country Representative until 2014. His experience in emergency and humanitarian action, communicable disease control, health system issues, mental health and a keen focus on addressing non communicable diseases in Sri Lanka have been well recognized and acknowledged. He is an Adjunct Professor at York University and University of Toronto in Canada, as well as a senior Mentor on several mentoring platforms. In recognition of his contributions to the Global Health Program at York, a Global Health student prize has been named after him in 2022. He is a member on the Governance and Advisory committee on Human Trafficking at the Peel Institute on Violence prevention, Family services Peel Toronto. Also a member on a Lived experience Advisory committee on research at the Centers for Addictions and Mental health (CAMH) Toronto. Member on the Steering Committee on Research for Mental Health Equity in the Asia Pacific – Digital (REMAP-D) based at the University of British Columbia (UBC). Advisor on “The Young Innovation Leaders Fellowship” Nigeria, which is a platform created by Hutzpah Centre for Innovation and Development - a social enterprise aimed at promoting innovation across sectors in AfricaResourcesFollow Dr. Mehta on LinkedIn Read more about Ali Maalin, the last man with smallpoxMultiPod Mentoring Learn more about Family Services of Peel Support the showJoin The Public Health Career Club: the #1 hangout spot and community dedicated to building and growing your dream public health career.

Ingrid Christensen is a Canadian still life and figurative oil painter. Ingrid was born in 1964 in Golden, British Columbia—a small town in the mountains in western Canada. She is the third of four children with an older sister and between two brothers. Ingrid's parents, John and Ella Anderson, were German immigrants who arrived in Canada after WWII and eventually made their way to running a motel. As a child, Ingrid was not exposed to the art world but she was keen on drawing, and is self taught as an artist. After high school, further education took her away from growing up in a small town to Vancouver where she earned a BA at the University of British Columbia (UBC). This was followed by a BEd from Queens University in Kingston, Ontario. Upon graduating, Ingrid spent a few years in teaching but eventually realized that this was not her calling. Once she married, she set off on bigger adventures; to Australia and New Zealand, and later to Japan, and Thailand where she learned the art of silversmithing. Upon returning to Calgary the couple started a family. It was then that Ingrid began her journey in painting; first in watercolors then later in oils, which is her preferred medium. Her art has won both national and international awards and has been highlighted in International Artist, Avenues, and Arabella magazines. Ingrid has written articles about art and creativity for Artsy online magazine. She says she is, first and foremost, a painter of light. Her work is an ongoing exploring of light's ability to elevate even the most mundane object into the glowing subject of a painting. When she is not painting, Ingrid is teaching either online or with in-person workshops. Ingrid has two sons, Zac and Ben, and is married to film producer David Christensen. She lives in Calgary, Alberta.Host: Chris StaffordProduced by Hollowell StudiosFollow @theaartpodcast on InstagramEmail: hollowellstudios@gmail.comIngrid's website: ingridchristensen.comIngrid on Instagram: @ingridchristensenartistIngrid's favorite female artists:Cecily BrownZoe FrankJennifer PochinskiErika SeguinJoanna LogueClaudia RillingLisa GolightlyAmy DuryAmy Brakeman LivezeyLucy StopfordCathy Chin (@realandplastic)Mary Beth MckenzieKaren Silve NataliaTomas SegoviaIngrid's Playlist:Aruna Chandra/Mashti, Deep Dive Corp.Kidz of Tibet/Kleintierschaukel, BadauIt's a Beautiful Day (Reprise)/The Kiffness, Rushawn, Jermaine EdwardsCassiopeia/Dan BayPoseidon/Dan Bay La RubriqueSeptember Fields/Frazey FordHeart of Glass/Lily MooreRighteously/Anna AshChaise Longue/Wet LegDowntown Train/Tom WaiteNever Going Back/Fleetwood MacAdriatica/OpezHallelijah (I'm a Dreamer)/Luther Dickinson, Amy LaVereSweet Dark-Haired Man/Joan ShelleyWalking on Broken Glass/Annie LennoxNot Fair/Lily AllenYou Know I'm No Good/Amy WinehouseHello (feat. Dragonette)/Martin Solveig, Dragonette 16 days ago #artists, #women0 COMMENTSThis show is part of the Spreaker Prime Network, if you are interested in advertising on this podcast, contact us at https://www.spreaker.com/show/4769409/advertisement

Ingrid Christensen is a Canadian still life and figurative oil painter. Ingrid was born in 1964 in Golden, British Columbia—a small town in the mountains in western Canada. She is the third of four children with an older sister and between two brothers. Ingrid's parents, John and Ella Anderson, were German immigrants who arrived in Canada after WWII and eventually made their way to running a motel. As a child, Ingrid was not exposed to the art world but she was keen on drawing, and is self taught as an artist. After high school, further education took her away from growing up in a small town to Vancouver where she earned a BA at the University of British Columbia (UBC). This was followed by a BEd from Queens University in Kingston, Ontario. Upon graduating, Ingrid spent a few years in teaching but eventually realized that this was not her calling. Once she married, she set off on bigger adventures; to Australia and New Zealand, and later to Japan, and Thailand where she learned the art of silversmithing. Upon returning to Calgary the couple started a family. It was then that Ingrid began her journey in painting; first in watercolors then later in oils, which is her preferred medium. Her art has won both national and international awards and has been highlighted in International Artist, Avenues, and Arabella magazines. Ingrid has written articles about art and creativity for Artsy online magazine. She says she is, first and foremost, a painter of light. Her work is an ongoing exploring of light's ability to elevate even the most mundane object into the glowing subject of a painting. When she is not painting, Ingrid is teaching either online or with in-person workshops. Ingrid has two sons, Zac and Ben, and is married to film producer David Christensen. She lives in Calgary, Alberta. Host: Chris StaffordProduced by Hollowell StudiosFollow @theaartpodcast on InstagramEmail: hollowellstudios@gmail.comIngrid's website: ingridchristensen.comIngrid on Instagram: @ingridchristensenartist Ingrid's favorite female artists: Cecily BrownZoe FrankJennifer PochinskiErika SeguinJoanna LogueClaudia RillingLisa GolightlyAmy DuryAmy Brakeman LivezeyLucy StopfordCathy Chin (@realandplastic)Mary Beth MckenzieKaren Silve NataliaTomas Segovia Ingrid's Playlist:Aruna Chandra/Mashti, Deep Dive Corp.Kidz of Tibet/Kleintierschaukel, BadauIt's a Beautiful Day (Reprise)/The Kiffness, Rushawn, Jermaine EdwardsCassiopeia/Dan BayPoseidon/Dan Bay La RubriqueSeptember Fields/Frazey FordHeart of Glass/Lily MooreRighteously/Anna AshChaise Longue/Wet LegDowntown Train/Tom WaiteNever Going Back/Fleetwood MacAdriatica/OpezHallelijah (I'm a Dreamer)/Luther Dickinson, Amy LaVereSweet Dark-Haired Man/Joan ShelleyWalking on Broken Glass/Annie LennoxNot Fair/Lily AllenYou Know I'm No Good/Amy WinehouseHello (feat. Dragonette)/Martin Solveig, Dragonette

In this episode, we sit down with Dr. Judy Illes and Anthony Hannan to discuss the International Brain Initiative – a coalition that seeks to catalyze and advance neuroscience through international collaboration and knowledge sharing. Dr. Illes is a Professor of Neurology and a Distinguished University Scholar in Neuroethics at the University of British Columbia (UBC). She is also the Director of Neuroethics Canada at UBC, and faculty in the Brain Research Centre at UBC and at the Vancouver Coastal Health Research Institute. Her work revolves around the intersection of neurosciences and biomedical ethics, specifically looking at them from an ethical, legal, social, and political perspective. Anthony Hannon is the Head of the Neural Plasticity Laboratory at Florey Neuroscience Institutes, and an Associate Professor at the University of Melbourne, Parkville, Australia. Currently, his research focuses on cognitive and psychiatric illnesses, including conditions like Huntington's disease. Offer: Magnesium is integral for 600+ biochemical processes in the human body. The common misconception is that consuming more magnesium will automatically improve health and well-being. The truth is that there are various forms of magnesium, each of which is essential for a variety of physiological processes. Most people are inadequate in all forms of magnesium, while even those considered "healthy" typically only ingest 1 or 2 kinds. Consuming all 7 of magnesium's primary forms is the key to accessing all its health benefits.That's why we packed 7 forms of 450mg of elemental magnesium into each serving of  Wild Mag Complex. One dose a day is all you need. Learn more and grab a bottle today at WildFoods.co. Use code GENIUS for 10% off your order. Join the conversation now to find out: What the International Brain Initiative is, and how it has evolved over the years. How big data is changing science, and the importance of sharing it internationally. Obstacles that exist in the peer-review process. What the open neuroscience movement is, and how it's expanding scientific research. Want to learn more about the International Brain Initiative? Click here now! Episode also available on Apple Podcasts: http://apple.co/30PvU9C

Амралтын өдрийн мэнд хүргэе. Та бүхэнтэй Podlogy багийн шинэ гишүүн Алтан-Очир (Chiro)-ын хамт IQ, танин мэдэхүйн чадварууд, оюун дүгнэлтийн алдаануудын талаар ярилцсан шинэ дугаараараа мэндчилж байна. Chiro University of British Columbia (UBC)-д сэтгэл судлалаар суралцдаг ба түүний мөрөөдөл нь хүн бүрт сэтгэл судлалын мэдлэг, мэдээллийг үнэ төлбөргүй хүргэх юм. Podlogy-д тавтай морил Chiro!

Meaghan Thumath is a practicing nurse, clinical assistant professor at the University of British Columbia (UBC), and the regional director of communicable disease control at Vancouver Coastal Health. She holds a Masters of Science in public health from the London School of Hygiene and Tropical Medicine, and a Ph.D. from the University of Oxford as a Trudeau scholar.Meaghan is an active member of the World Health Organization's WHO Emergencies Programme (WHE) with recent deployments to support the COVID-19 response in South Africa and the Ebola Response in the Democratic Republic of Congo. I invited Meaghan on the program to share her expertise on the topic of harm reduction policies here in North America. During our time together, we talk about her experience as a street nurse, her own purview on the topic of substance abuse, and her hope of a dignified national approach to assist our growing homeless and addicted populations worldwide.Meaghan's love and attention to our world's most marginalized communities is even more impressive than her storied experience and education. I hope you learn as much from her as I did.Watch Episode: This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit truethirty.substack.com/subscribe

Jim Girvan is a Registered Professional Forester (RPF) who has dedicated over four decades of his life to the British Columbia forest industry. Jim's name is synonymous across North America in respect to fibre supply forecasting and the varied lobby efforts on the part of independent timber harvesting contractors, consultants, forest licensees, and investors. Residing in Ladysmith. BC, Jim is a recipient of the Distinguished Forest Professional Award from the Association of BC Forest Professionals. He has previously served as Executive Director of the Truck Loggers Association of BC, and has advocated for the forest industry through various articles and speaking engagements. Girvan earned a Masters of Business Administration from the University of British Columbia (UBC) and is the author of the book '

Visit The Culture Works if you'd like a free download of Chapter One, Duck SyndromeWe hope the time you spend with us will help remove the stigma of anxiety and mental health in the workplace and your personal life.In this episode you will learn: - Why leaders don't acknowledge anxiety, and why they should- How resilience impacts anxiety- 4 ways leaders create psychological safety at work Our guest today is Dr. Marie-Helene Pelletier (MH) is a bilingual, practicing resilience and anxiety psychologist and experienced senior leader with over 20 years of experience in clinical, counseling, workplace psychology. One of her key areas of focus is leadership resilience. She holds a Ph.D. in counseling psychology from the University of British Columbia (UBC) and an MBA from the UBC Sauder School of Business.Her takeaways for us are: - Separate the probability from the possibility - Stay Curious###Until next week, we hope you find peace & calm in a world that often is a sea of anxiety.If you love this podcast, please share it and leave a 5-star rating! If you feel inspired, we invite you to come on over to The Culture Works where we share resources and tools for you to build a high-performing culture where you work.Your hosts, Adrian Gostick and Chester Elton have spent over two decades helping clients around the world engage their employees on strategy, vision and values. They provide real solutions for leaders looking to manage change, drive innovation and build high performance cultures and teams. They are authors of award-winning Wall Street Journal & New York Times bestsellers All In, The Carrot Principle, Leading with Gratitude, & Anxiety at Work. Their books have been translated into 30 languages and have sold more than 1.5 million copies. Visit The Culture Works for a free Chapter 1 download of Anxiety at Work.Learn more about their Executive Coaching at The Culture Works. christy@thecultureworks.com to book Adrian and/or Chester to keynote

In this “journal club” edition of the podcast, we are joined by the thoughtful trauma guru Dr. Hameed to talk about his paper in the Canadian Journal of Surgery (CJS). This paper, authored by Drs. Ball, Lee, Kaminsky, and Hameed gets at the “heart” of both the decision-making and technical aspects of treating penetrating cardiac injuries. YouTube version: https://youtu.be/_g6Nu66Q3AM YouTube channel: https://www.youtube.com/@coldsteelsurgery Links: 1. Technical considerations in the management of penetrating cardiac injury: https://www.canjsurg.ca/content/65/5/E580 2. Sternotomy or drainage for a hemopericardium after penetrating trauma: a randomized controlled trial. https://pubmed.ncbi.nlm.nih.gov/23604058/ 3. A caveat to the Performance of Pericardial Ultrasound in Patients with penetrating Cardiac Wounds. https://pubmed.ncbi.nlm.nih.gov/19901678/ Morad Hameed Bio: Dr. Morad Hameed is a trauma surgeon and intensivist at the Vancouver General Hospital (VGH) and an Assistant Professor of Surgery at the University of British Columbia (UBC). He completed medical school and surgical residency at the University of Alberta, graduate studies in public health at Harvard University, and fellowships in Trauma Surgery and Surgical Critical Care at the University of Miami. He spent 3 years on the surgical faculty at the University of Calgary, before moving to Vancouver. He is the Head of the UBC and VGH Division of General Surgery and is a Service Chief for Acute Care Surgery at VGH. He also chairs the Research Committee of the Trauma Association of Canada, and is the immediate past chair of the Canadian Association of General Surgeons Committee on Acute Care Surgery. His research focuses on systems of trauma care and acute care surgery. Dr. Hameed's research teams have received grants from the Canadian Institutes for Health Research, the Michael Smith Foundation for Health Research, and other funding agencies for their work on disparities in injury risk and access to trauma systems in Canada. The development of promising partnerships with trauma investigators at the University of Cape Town has recently extended this work to South Africa.

Generalized anxiety disorder (GAD) can at times be difficult to differentiate from the anxious distress that can accompany depression, health anxiety, some presentations of OCD and even social anxiety.  As well GAD, is often treated as a “catch-all” diagnosis that is applied to any client expressing distress. One of Canada's leading voices in the understanding and treatment of GAD, Dr. Melisa Robichaud joins us for an extensive discussion of GAD with respect to: Generalized anxiety disorder (GAD) from a diagnostic lensuncertainty as being a key challenge within the context of GADthe developmental experiences & biological factors that might predispose someone towards developing GADwhether anxiety disorders in childhood reliably predict GAD in adulthoodthe evolution of GAD over the developmental lifespan and whether GAD gets worse with ageuseful features of GAD to be aware of that do not necessarily fall within the diagnostic framework but that would nonetheless be useful for clinicians to keep in minddifferentiating between GAD and the “anxious distress” that can so frequently accompany an episode of major depression applicability of ACT and other 3rd wave CBT therapies to GADthe vital importance of psychoeducation and pacing of therapy in the treatment of GADthe role of medication in the treatment of GADComments or feedback?  Email the show: oicbtpodcast@gmail.comDr. Melisa Robichaud received her Ph.D. in clinical psychology at Concordia University in Montreal. She is currently an adjunct faculty member in the Department of Psychology at the University of British Columbia (UBC), a clinical instructor in the UBC Department of Psychiatry, and a clinical associate in the Department of Psychology at Simon Fraser University (SFU). She is also certified as an expert in cognitive-behavioural therapy by the Canadian Association of Cognitive and Behavioural Therapies (CACBT).  Dr. Robichaud worked in the former Anxiety Disorders Clinic of UBC Hospital, where she provided assessment and treatment to anxiety disorder patients. She also trained and supervised psychiatry and psychology residents in how to assess, diagnose, and treat anxiety disorders.  Dr. Robichaud has been actively involved in non-profit organizations dedicated to the dissemination of best practice treatment for individuals struggling with anxiety disorders. She is a former President of CACBT (2016-2019), and is on the CACBT Certification Task Force. She also served on the Board of Directors of Anxiety Canada (formerly AnxietyBC) from 2006 to 2010, was the Director of Programs (2007-2010), and is currently on the Anxiety Canada Scientific Advisory Board. Dr. Robichaud's area of specialization is cognitive-behaviour therapy (CBT) for anxiety disorders. She has established expertise in treating generalized anxiety disorder (GAD), obsessive-compulsive disorder (OCD), health anxiety (also called illness anxiety or hypochondriasis), panic disorder, social anxiety disorder, body-focused repetitive behaviours (e.g., hair pulling, skin picking), and post-traumatic stress disorder. Dr. Robichaud's particular area of expertise is CBT for GAD. She ran the GAD treatment program at the former Anxiety Disorders Clinic of UBC Hospital, and has provided workshops to professionals internationally on how to recognize and treat GAD. She has published numerous scientific articles and book chapters on the subject, as well as co-authoring several books on the treatment of GAD, including “Cognitive-Behavioral Treatment for Generalized Anxiety Disorder: From Science to Practice” (2ndedition), "The Generalized Anxiety Disorder Workbook: A Comprehensive CBT Guide for Coping with Uncertainty, Worry, and Fear", and “The Worry Workbook: CBT Skills to Overcome Worry and Anxiety by Facing the Fear of Uncertainty”.

Rob Schuetz is the President of Industrial Forestry Service (IFS), which is one of the largest natural resource consulting firms operating in British Columbia for the forestry, bioenergy, oil & gas, and mining sectors. Rob is past-president of the Society of Consulting Foresters of British Columbia. He specializes in the analysis of fibre supplies throughout BC and Alberta and has spent over 25 years consulting to the natural resource industries. In this regard he has undertaken due-diligence assessments of biomass fuel plans in support of over 50 proposed bioenergy projects; log supplies in support of sawmill acquisitions, economic assessments of the impact of a mountain pine beetle epidemic on timber supplies across Canada; delivered log cost optimization analysis to multiple delivery points and sawmill operating rate forecasts. Rob graduated with a B.Sc. in Forestry from the University of Toronto in 1987. Jim Girvan is a Registered Professional Forester (RPF) who has dedicated over four decades of his life to the British Columbia forest industry. Jim's name is synonymous across North America in respect to fibre supply forecasting and the varied lobby efforts on the part of independent timber harvesting contractors, consultants, forest licensees, and investors. Residing in Ladysmith. BC, Jim is a recipient of the Distinguished Forest Professional Award from the Association of BC Forest Professionals. He has previously served as Executive Director of the Truck Loggers Association of BC, and has advocated for the forest industry through various articles and speaking engagements. Girvan earned a Masters of Business Administration from the University of British Columbia (UBC) and is the author of the book '

Jim Girvan is a Registered Professional Forester (RPF) who has dedicated over four decades of his life to the British Columbia forest industry. Jim's name is synonymous across North America in respect to fibre supply forecasting and the varied lobby efforts on the part of independent timber harvesting contractors, consultants, forest licensees, and investors. Residing in Ladysmith. BC, Jim is a recipient of the Distinguished Forest Professional Award from the Association of BC Forest Professionals. He has previously served as Executive Director of the Truck Loggers Association of BC, and has advocated for the forest industry through various articles and speaking engagements. Girvan earned a Masters of Business Administration from the University of British Columbia (UBC) and is the author of the book '

In this episode Eric, along with special guest host Matt Genuchi from Boise State University in Boise, ID, interviewed John Oliffe from the University of British Columbia (UBC) in Vancouver, British Columbia, Canada.  John is the founder of the UBC Men's Health Research Program, where a primary focus is on mental health, understanding depression and suicide, and offering active community intervention programs (in Canada and Australia).  His academic training begins as a nurse in Australia, later earning a PhD in health sciences.  These experiences in hospital emergency rooms and with family members help shape John's motivation to understand men's health issues better, but moreover, understand their pain and then design interventions (and test their effectiveness) to provide help. Follow UBC Men's Health Research on Twitter: @MensHealthUBC  

Welcome to The Nonlinear Library, where we use Text-to-Speech software to convert the best writing from the Rationalist and EA communities into audio. This is: Introducing new leadership in Animal Charity Evaluators' Research team, published by Animal Charity Evaluators on November 17, 2022 on The Effective Altruism Forum. Introduction Hello EA Forum! As some of you may already be aware, Animal Charity Evaluators (ACE) has recently expanded our team, most notably in Research. As such, we'd like to introduce ourselves as ACE's new Director of Research and Evaluations Program Manager and share how we intend to engage the EA community via this forum moving forward. We both joined ACE this summer, right as the annual charity evaluation season kicked off. Since we were hired, two new researchers, Alina Salmen, Ph.D. and Max Taylor, have joined, as well as our new Executive Director, Stien van der Ploeg. Our Backgrounds Elisabeth Ormandy - Director of Research I have an academic background in Neuroscience (B.Sc.), Applied Animal Behaviour and Welfare (M.Sc.), and Animal Welfare and Ethics (Ph.D.). I completed a research fellowship in animal policy development for the Canadian Council on Animal Care and held a post-doctoral fellowship position at the University of British Columbia (UBC). I also taught various undergraduate courses at UBC including: Animals and Society, Animals and Global Issues, Scholarly Writing and Argumentation, and Animals, Politics and Ethics. In 2015, I opted to leave academia to co-found the Canadian Society for Humane Science—I served as their Executive Director until I joined ACE. In that role, I gained experience in nonprofit management, impact assessment, and strategic planning, and learned the importance of strengthening the animal advocacy movement. Alongside my paid work in animal advocacy, I currently serve in a number of volunteer roles, most notably as a Board member for the Association for the Protection of Fur-Bearing Animals. Vince Mak - Evaluations Program Manager I have a generalist background—I graduated from the Wharton School at the University of Pennsylvania and spent the beginning of my career in financial services. I discovered effective altruism in 2019, developed an interest in animal advocacy after reading Animal Liberation in 2020, and began doing EA-style charity evaluations across cause areas as a volunteer with SoGive in 2021. Outside of my job at ACE, I currently assist in various capacities with EA research, grantmaking, and movement building. ACE's Next Steps on the EA Forum Our intentions In the past few years, ACE's activity on the EA Forum has been to provide updates on our work and share our thinking. As an EA organization dedicated to transparency and intellectual rigor, we would like to take it a step further and interact more closely with the community that shares these values. As we tinker with our evaluation methodology in the months and years ahead, we plan to invite your feedback during the intermediate stages; we do not want to just inform you, we want to be informed by you. In addition to opportunities to critique our thinking, you can also expect from ACE transparency about our processes, responsiveness to fair and genuine criticism, and a commitment to evolve our thinking in response to new evidence. Adjustments to our evaluations process so far This year, our research team altered the way we approach our evaluations, partially thanks to input from people on this forum in the past. For instance, we have now implemented quantitative scoring frameworks for our Programs and Cost Effectiveness evaluation criteria—a marked departure from how we assessed these criteria last year. We appreciate the EA community's willingness to provide constructive criticism so that we can continually refine our methods. More recently, some of you have already volunteered your time and expertise by sharing proposals for how ACE can improve. In particular, we thank Nuno Sempere for a th...

Data are the lifelines of a digital economy. They drive innovation, enabling cutting-edge research and next-generation technologies, including artificial intelligence (AI), robotics, and the Internet of things (IoT). But these opportunities introduce new sources of risk that must be managed appropriately. Canadians are raising important questions such as, “How will personal data be used?” and “What controls are in place to safeguard privacy and security?”  To encourage innovation within the digital economy while managing this risk, the Government of Canada has established the need for digital trust between citizens and organizations as an enabler by implementing a Digital Charter. As the Canadian government cites, “Trust is the foundation on which our digital and data-driven Canadian economy will be built.” This digital trust is defined by the “confidence that users have in the ability of people, technology, and processes to create a secure digital world. Tune into this ISACA Podcast as the Acting Director of Internal Assurance at the Office of Enterprise Risk & Assurance of the University of British Columbia (UBC), Mary Carmichael, join's ISACA's Safia Kazi to explore topics including what is the Digital Charter and how it supports digital trust; what are critical elements of the Digital Charter (e.g., AI Ethics, Privacy, Principles for the Digital Economy); what are the implications for organizations and the public.   To read Mary's full-length article, visit https://www.isaca.org/enabling-digital-trust-with-canadas-digital-charter.

Tahia Devissher is a Banting Research and Teaching Fellow at the University of British Columbia (UBC) Faculty of Forestry. She studies how to manage forests and other greenspaces in and around cities to support human well-being and build social-ecological resilience to climate change. She is also interested in developing practical strategies to strengthen the relationship between urbanites and nature. In past work with the Stockholm Environment Institute, Tahia led research to support climate change adaptation working with local communities, NGOs, and governments in more than 20 countries across the Global South. In most of her projects, she applies interdisciplinary approaches by integrating methods from quantitative modelling to participatory mapping, and qualitative assessment. Tahia has a Ph.D. in ecosystems science from the University of Oxford. --- Support this podcast: https://anchor.fm/plantatrilliontrees/support

When it comes to the fertility journey, it's more like a marathon than a sprint. And just like a marathon requires weeks and months of training to run a good race, creating healthy embryos requires preconception training, too. Our goal is not just for you to start the race but to cross the fertility finish line with a baby in your arms. With patience, testing, and the right treatments, you can greatly increase your chances of having a healthy baby. In this episode, I get more technical with Dr. Beth Taylor from Olive Fertility Centre to talk about the different fertility tests and screenings IVF clinics can provide to assess the quality of your embryos as well as your uterine receptivity (any risk of implantation failure) in order to increase the chances of positive pregnancy and live birth. IVF treatments have come a long way in the past couple of decades, and it's important that we educate those on the fertility journey about everything we can offer to give them the best chance of a positive outcome. We know you want the best for your family and to be made aware of the testing and treatments available to you, so please join us to learn about your options and why preimplantation genetic testing and uterine biopsies might be a choice for you to help grow your family.   Key Topics/Takeaways: Nourishing the “seed and the soil” [2:55] Using PGT-A testing to increase implantation odds [9:56] The mosaic embryo dilemma [17:00] How self-correction in Chinese medicine applies to IVF [19:44] Creating healthy embryos is a marathon, not a sprint [22:48] Testing uterine receptivity [27:17]  The importance of the uterine microbiome [37:31] Keeping your embryos safe during testing [50:01]   Dr. Taylor is an infertility specialist. She is a co-founder and co-director of Olive Fertility Centre in Vancouver BC where Acubalance Wellness Centre offers IVFacupuncture onsite. After completing her medical degree at Dalhousie University in 1998, Dr. Taylor MD, FRCSC moved to British Columbia to do her residency in Obstetrics and Gynecology at the University of British Columbia (UBC). She subsequently completed a fellowship in Reproductive Endocrinology and Infertility and then joined Genesis Fertility Centre. Dr. Taylor worked at Genesis Fertility Centre until 2013, when she helped establish the Olive Fertility Centre. She is a Clinical Associate Professor at UBC. She is also an active staff member at BC Women's Hospital and Vancouver General Hospital. Dr. Taylor has also published several papers in peer-reviewed journals and has written three book chapters. Dr. Taylor loves the challenge and science of IVF for people struggling to conceive. She likes to try new ideas and new IVF protocols to get the best outcomes for Olive patients. She keeps up to date with the research literature and is open to trying novel procedures to try and solve even the most challenging fertility problems. Where To Find Dr. Beth Taylor: Olive Fertility Centre  Instagram (@olivefertility) To connect with Lorne Brown online and in person (Vancouver, BC), and to set IVF acupuncture appointments if you are going to Olive IVF clinic, visit:  Acubalance.ca Lornebrown.com   Connect with Lorne and the podcast on Instagram: https://www.instagram.com/acubalancewellnesscentre/ Instagram: @conscious_fertility_podcast Instagram: @lorne_brown_official DISCLAIMER: By listening to this podcast, you agree not to use it as medical advice to treat any medical condition in either yourself or others. This podcast offers information to help the listener cooperate with physicians, mental health professionals or other healthcare providers in a mutual quest for optimal well-being. We advise listeners to carefully review and understand the ideas presented, and to consult your own physician for any medical issues that you may be having. Under no circumstances shall Acubalance, any guests or contributors to the Conscious Fertility podcast, or any employees, associates, or affiliates of Acubalance be responsible for damages arising from the use of the podcast.

In this episode I welcome back Professor Nicola Hodges. This time Nikki is joined by Dr Keith Lohse. Nikki is a Professor at the University of British Columbia (UBC), Vancouver in the School of Kinesiology. She runs the Motor Skills Laboratory at UBC where she studies the mechanisms of motor skill learning. Her research focuses on processes involved in watching, learning and predicting from others, and how practice should be best structured to bring about long-term enhancement of motor skills and high-level performance. She has published over 100 peer-reviewed articles and chapters and has consulted at a number of leading sporting organisations and governing bodies. Dr Keith Lohse is Associate Professor of Physical Therapy and Neurology at Washington University School of Medicine in St Louis. He received his PhD in cognitive psychology from the University of Colorado, before undertaking post doctoral studies in Nikki's lab at UBC. Keith focuses on measurement, design, and analysis as they pertain to rehabilitation science and clinical practice. With rehabilitation being a complex, dynamic process with many interacting factors at physiological, psychological, and sociological levels, Keith specialises in analytical and predictive modelling techniques to help disentangle these problems and mechanistically explore the rehabilitation process. In this episode, we discuss a paper Nikki and Keith have co-authored titled: “An extended challenge-based framework for practice design in sports coaching” found here https://www.researchgate.net/publication/357785323_An_extended_challenge-based_framework_for_practice_design_in_sports_coaching which builds on the original challenge-point work published 20 years ago. Specifically, they emphasise the importance of the challenge-point framework as a model of motor learning, and expand this framework to apply to sports coaching (giving practical suggestions for coaches to use in their practice).

Sophie Nitoslawski is passionate about finding ways to better integrate trees and green infrastructure into the fabric of our cities. Her research centers on the intersection of smart communities and urban forest management, and she works with both private- and public-sector partners to pilot digital-based monitoring and management systems for urban ecosystems. In addition to her Ph.D. work, Sophie is involved in teaching various urban forestry and sustainability courses at University of British Columbia (UBC) and is currently a member of the International Society of Arboriculture (ISA) Science and Research Committee. --- Support this podcast: https://anchor.fm/plantatrilliontrees/support

On this third episode of The Trip Diary, Steve Tornes speaks with Councillor Tony Valente and Dr. Meghan Winters talks about cycling, advocacy, and street allocations. Tony describes his advocacy work before being elected to council, and what steps transportation advocates can take in other cities, as well as the development of Esplanade Street as a complete street. Meghan talked about her different research looking at cycling and street reallocations across different North American cities, and making the data available for city planners and members of the public. Full episode details: https://www.sfu.ca/vancity-office-community-engagement/below-the-radar-podcast/series/the-trip-diary/181-cycling-in-numbers.html Read the transcript: https://www.sfu.ca/vancity-office-community-engagement/below-the-radar-podcast/transcripts/181-cycling-in-numbers.html Resources: Councillor Tony Valente: https://www.tonyvalente.ca/about-tony/ Dr. Meghan Winters: https://www.sfu.ca/fhs/about/people/profiles/meghan-winters.html HUB Cycling: https://bikehub.ca/ Esplanade Complete Street: https://letstalk.cnv.org/esplanade-complete-street CHATR Lab: https://chatrlab.ca/ Bike Maps: https://bikemaps.org/ Impacts of Bicycle Infrastructure in Mid-Sized Cities (IBIMS): protocol for a natural experiment study in three Canadian cities: https://pubmed.ncbi.nlm.nih.gov/29358440/ COVID-19 street reallocation in midsize Canadian cities: https://pubmed.ncbi.nlm.nih.gov/33650060/ Not quite a block party: COVID-19 street reallocation programs in Seattle, WA and Vancouver, BC: https://www.sciencedirect.com/science/article/pii/S2352827321000446 WalkRollMap: https://chatrlab.ca/projects/walk-roll-map/ Bio: Tony Valente is a first term City Councillor. Tony has an MBA from UBC and for the last twelve years he has worked as a project manager delivering complex infrastructure projects in the public sector. Tony is currently working as a Risk Director with a Crown corporation. Tony envisions a vibrant, diverse City of North Vancouver where transportation and housing options abound, and our public spaces are the envy of Metro Vancouver. All of this is supported by a strong local economy where small business thrives. Dr. Meghan Winters is an epidemiologist interested in the link between health, transportation, and city design. She received her PhD in 2011 from the School of Population and Public Health at the University of British Columbia (UBC). She completed a post-doctoral fellowship at the Centre for Hip Health and Mobility at Vancouver Coastal Health Research Institute, studying on older adults' mobility and the built environment. Dr. Winters joined the Faculty of Health Sciences as an Assistant Professor in July 2011. Cite this episode: Chicago Style Tornes, Steve. “Geographies of Identity — with Councillor Tony Valente and Dr. Meghan Winters” Below the Radar, SFU's Vancity Office of Community Engagement. Podcast audio, July 19, 2022. https://www.sfu.ca/vancity-office-community-engagement/below-the-radar-podcast/episodes/181-geographies-of-identity.html.

Hosts: Demitria WackGuest: Maria "Masha" AruzumanovProduction and Marketing: Jarrett Ramones, Ellinor Arzbaecher, Kody Stoebig, and Tim HaydockMaria worked in economic research at the University of British Columbia (UBC) and Rheinisch-Westfälische Technische Hochschule (RWTH) Aachen University, undertaking projects in gender and ethnic discrimination. She also interned with the Market Research team at the Federal Reserve, and the Bureau of Western Hemisphere Affairs at the U.S. Department of State.Maria graduated from UBC with a BA in economics and a minor in business. Her dissertation focused on unequal transit access in Chicago's historically Black neighborhoods. She also holds a MSc in political science and political economy from the London School of Economics (LSE), with a dissertation in representation and accountability of US government officials.We'd Love to Hear from You! Clink the link below to fill out a quick survey and let us know what you think!https://www.surveymonkey.co.uk/r/QLVPBCTFollow us on social @policywisepod on Twitter, Instagram and Facebook! And don't forget to subscribe and rate us on iTunes. See you next time on PolicyWise!

Zhaohua (Cindy) Cheng is a Ph.D. candidate in urban forestry at the University of British Columbia (UBC). She has over five years of experience in community and youth engagement, climate change adaptation, student advising and engagement, and project management. Her Ph.D. research focuses on exploring urban forest-based solutions for climate resilience and urban livability. --- Support this podcast: https://anchor.fm/plantatrilliontrees/support

SPP 145: Developmental Psychology and SEL Please join #psychedpodcast in welcoming Dr. Schonert-Reichl! Dr. Kimberly Schonert-Reichl Dr. Kimberly Schonert-Reichl is an Applied Developmental Psychologist and a Professor in the Human Development, Learning, and Culture area in the Department of Educational and Counselling Psychology, and Special Education at the University of British Columbia (UBC). She is… Continue reading SPP 145: Developmental Psychology and SEL

In this episode we talk with Patrick Baylis about productivity and work habits. Patrick Baylis is an assistant professor and environmental economist at the Vancouver School of Economics at the University of British Columbia (UBC). He studies how people respond to environmental threats like climate change, air pollution, and wildfires. Sebastian Tello-Trillo is an Assistant Professor of Public Policy and Economics at the Frank Batten School of Leadership and Public Policy in the University of Virginia. Alex Hollingsworth is an Associate Professor of Economics at the O'Neill School of Public and Environmental Affairs in Indiana University. Notes from the episode An updated blog post from Patrick that we reference throughout the episode, https://www.patrickbaylis.com/blog/2022-02-09-productivity/ Patrick's working paper: Mandated vs. Voluntary Adaptation to Natural Disasters: The Case of U.S. Wildfires (with Judson Boomhower), https://www.nber.org/papers/w29621 Watch Patrick on ESPN: https://www.youtube.com/watch?v=N9m9o0X7MN8 Make time book: https://bookshop.org/shop/Hiddencurriculum Recommendations of the Week Patrick recommends deleting email applications from your phone. Alex recommends buying a kitchen scale (he has this one Escali Primo P115C). (Note: Sebastian has now done this and also endorses this tip) Sebastian recommends wakelet (https://wakelet.com) to organize lists of links --- Send in a voice message: https://anchor.fm/hidden-curriculum/message

Tuesday and Tim are joined by Dr. Robert Strang, Nova Scotia's Chief Medical Officer of Health, where they discuss the topic on EVERYONE'S MIND these days, COVID (and the Omicron variant!), his personal leadership, and public health. As the one leading the charge of the response to the COVID-19 pandemic in Nova Scotia, how does he continue to hold his centre and what is he learning?About Dr. Robert Strang:Dr. Robert Strang is Chief Medical Officer of Health in Nova Scotia appointed in August 2007. He received his medical degree from University of British Columbia (UBC) and completed Family Practice and Public Health and Preventive Medicine residencies at UBC.As Chief Medical Officer of Health, he has provided leadership around the renewal of the public health system in Nova Scotia as well as raising awareness around the importance of creating policies and environments that support better health for Nova Scotian families and communities.He is passionate about public health and has worked with non-government organizations such as Smoke Free Nova Scotia, Heart and Stroke Foundation and Public Health Association of Nova Scotia.Dr. Strang has an adjunct appointment with Dalhousie University, Department of Community Health and Epidemiology.Resources:Learn more about, and follow, The Outside by visiting and liking all of our channels:Website: www.findtheoutside.comFacebook & Instagram: @findtheoutsideLinkedIn: https://www.linkedin.com/company/findtheoutsideWindhorse Farm transferred to Mi'kmaq in spirit of reconciliationNova Scotia Health See acast.com/privacy for privacy and opt-out information.